

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI XDC CAYMAN INC.

藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2268)

**(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS;
AND
(2) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of WuXi XDC Cayman Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Stewart John Hen (“**Mr. Hen**”) has tendered his resignation as an independent non-executive Director and a member of each of the audit committee, remuneration committee and strategy committee of the Board (together, the “**Committees**”), with effect from November 21, 2024 in order to devote more time to his other personal commitment.

Mr. Hen has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its gratitude to Mr. Hen for his valuable contribution to the Company during his tenure of service as an independent non-executive Director and member of the Committees.

The Board is also pleased to announce that Mr. Kenneth Walton Hitchner III (“**Mr. Hitchner**”) has been appointed as an independent non-executive Director with effect from November 21, 2024.

The biographical details of Mr. Hitchner are as follows:

Mr. Kenneth Walton Hitchner III, aged 64, has more than 30 years of experience in corporate finance. He served as the Chairman and Chief Executive Officer of The Goldman Sachs Group, Inc. in Asia Pacific Ex-Japan before his retirement in 2019. He was also a member of Goldman Sachs’ Management Committee and co-chaired its Asia Pacific Management Committee. Previously, Mr. Hitchner served as President of Goldman Sachs in Asia Pacific Ex-Japan from 2013 to 2017. Prior to relocating to Hong Kong, he was global

head of Goldman Sachs' Healthcare Banking Group and global co-head of its Technology, Media and Telecom Group. He was named managing director in 2000 and partner in 2002. He became head of the global medical device banking practice in 1998 and head of the global pharmaceutical banking practice in 2001. He began his career with Goldman Sachs' Corporate Finance Department in 1991. Mr. Hitchner has been serving as a director of the alternative investment management firm Elements Advisors SPV since May 2020. He has joined Global Advisory Board of the global early-stage venture capitalist Antler since January 2021. He has also been serving as a senior advisor of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (Shanghai Stock Exchange stock code: 603259 and Stock Exchange stock code: 2359) since February 2020. From January 2021 to October 2022, Mr. Hitchner served as an independent non-executive director of Provident Acquisition Corp., a company listed on NASDAQ and delisted in October 2022. Since February 11, 2021, Mr. Hitchner has also been serving as the chairman of the board of HH&L Acquisition Co., a company listed on the New York Stock Exchange (stock code: HHLA) and delisted in 2024. Mr. Hitchner has been serving as an independent non-executive director of WuXi Biologics (Cayman) Inc. (stock code: 2269) since June 9, 2020 and as a non-executive director of CStone Pharmaceuticals (stock code: 2616) since December 10, 2021. Save as disclosed above, Mr. Hitchner does not, at present, nor did he in the past three years, hold any directorship in any public companies the securities of which are listed in Hong Kong or overseas.

Mr. Hitchner obtained a bachelor's degree in arts from the University of Colorado in 1982 and a master's degree in business administration (MBA) as a merit fellow from Columbia University Business School in 1992.

Mr. Hitchner has entered into a director's appointment letter with the Company for a term of three years which is terminable by either party with one month's written notice, and he is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company. Save as disclosed above and except for acting as an independent non-executive Director and holder of 203,205 shares of WuXi Biologics (Cayman) Inc. as at the date of this announcement, Mr. Hitchner does not have any relationships with any Directors or senior management or substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, Mr. Hitchner did not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Hitchner is entitled to director's fee of HK\$1,200,000 per annum which is determined with reference to his experience and responsibilities with the Company, the prevailing market conditions, the terms of the remuneration policy of the Company and the recommendation from the remuneration committee.

Mr. Hitchner has confirmed that (i) he is independent as regards to each of the criteria set out in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on Stock Exchange (the "**Listing Rules**"); (ii) save as disclosed above, he has no past or present financial or other interest in the business of the Group or any connection with any core connected persons (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there is no other information which is discloseable nor is/was Mr. Hitchner involved in any of the matters required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of Listing Rules and there are no other matters relating to Mr. Hitchner's appointment that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board further announces that Mr. Hitchner has been appointed as a member of each of the audit committee, remuneration committee and strategy committee of the Board with effect from November 21, 2024.

The Board would like to extend its warmest welcome to Mr. Hitchner on his new appointment.

By order of the Board
WuXi XDC Cayman Inc.
Dr. Jincal LI
Executive Director and Chief Executive Officer

Hong Kong, November 21, 2024

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincal LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Dr. Weichang ZHOU and Ms. Ming SHI as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton HITCHNER III and Mr. Hao ZHOU as independent non-executive directors.

* *For identification purpose only*